tiprankstipranks
Delcath Systems Reports Strong 2024 Financial Performance
Company Announcements

Delcath Systems Reports Strong 2024 Financial Performance

Story Highlights

Stay Ahead of the Market:

Delcath Systems ( (DCTH) ) has shared an update.

Delcath Systems announced preliminary, unaudited financial results for the fourth quarter and full year 2024, reporting expected revenues of $15.1 million for the quarter and $37.2 million for the year. The company highlighted strong sales from its HEPZATO KIT, and maintained a robust cash position of $53.2 million with no debt, suggesting stable financial health and positive operational performance going forward.

More about Delcath Systems

Delcath Systems, Inc. is an interventional oncology company specializing in treatments for primary and metastatic liver cancers. Its main products are the HEPZATO KIT™ and CHEMOSAT® Hepatic Delivery System, designed to administer high-dose chemotherapy to the liver with controlled systemic exposure.

YTD Price Performance: -8.96%

Average Trading Volume: 399,690

Technical Sentiment Consensus Rating: Buy

Current Market Cap: $367.1M

Learn more about DCTH stock on TipRanks’ Stock Analysis page.

Related Articles
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App

Latest News Feed

More Articles